Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.